Palifosfamide

    • Catalog No.:MC1378
      • CasNo:
      • 31645-39-3
      • MolecularFormula:
      • C4H11Cl2N2O2P
      • Purity:
      • >98%
      • Target:
      • DNA Alkylator/Crosslinker
      • IC50:
      • No data
      • In Vitro:
      • Palifosfamide lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma lines in vitro. The IC50 ranges from 2.25 ro 6.75 μM for most cell lines except OS222 (IC50=31.5 μM)[1].
      • In Vivo:
      • Tumor growth inhibition is seen in both OS31 and OS33 xenografts and the RMS xenograft resulting in a significant difference in event-free survival between the control and the treated groups. Differential gene expression of ALDH3A1 but not ALDH1A1 is noted in the OS31 xenograft[1]. Stabilized palifosfamide administered to mice suppresses MX-1 tumor growth by greater than 80% with 17% complete antitumor responses. Oral bioavailability in rats is 48-73% of parenteral administration, and antitumor activity in mice is equivalent by both routes. Treatment with palifosfamide-tris combined with docetaxelor doxorubicin at optimal regimens results in complete tumor regression in 62-75% of mice[2].
      • Fields:
      • Palifosfamide is a novel molecule for the treatment of sof tissue sarcoma.
      • Specificity:
      • Target: DNA Alkylator/Crosslinker. Fields: Palifosfamide is a novel molecule for the treatment of sof tissue sarcoma.
      • Concentration:
      • >98%
      • Storage Stability:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • MolecularWeight(Da):
      • 221.02
      • References:
      • [1]. Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-
      • Products Images